EDGE
Book a demo

Psychedelic Medicine

Promising research and receding stigma are giving investors cannabis-boom flashbacks.

Overview

The psychedelic renaissance: moving beyond stigma toward a breakthrough mental health treatment

Psychedelics (also called hallucinogens) are powerful mind-altering substances that can temporarily induce hallucinations by affecting the serotonin receptors in the brain responsible for controlling the senses. Popular psychedelics include lysergic acid diethylamide (LSD/acid), psilocybin (magic mushrooms), and ketamine.

Psychedelics have been used in religious settings for thousands of years, but developed a social stigma in the 1960’s due to widespread recreational use by “hippies” and youth involved in counter-cultural and anti-war movements in the US and beyond. These substances were finally made illegal in the US in 1970. Fifty years later, psychedelics are re-entering the mainstream as a potential breakthrough for various hard-to-treat mental health conditions, including depression and post-traumatic stress disorders (PTSD).

A May 2019 approval by the US Food and Drug Administration (FDA) of a ketamine-derivative substance (in therapeutic settings) has raised the possibilities of more widespread commercialization of psychedelics. Since then, the nascent industry—still mostly in the research stage—has garnered significant investor interest, some of whom are anticipating a cannabis-like boom.

What's driving this industry?
Market Sizing

The US addressable market estimate for FDA-approved depression and PTSD therapies is USD 66 billion

View details

COVID-19 IMPACT

Heightened demand for mental health treatments:  

In June 2020:

- 4X higher rates of depression (vs Q2 2019)

- 3X higher rates of anxiety (vs Q2 2019)

- 2X higher rates of suicidal ideation (vs 2018)

Pandemic restrictions forced psychedelic clinics to adopt telemedicine:

  • Field Trip: Launched virtual psychedelic therapy services through its online platform.

  • Mindbloom: Launched fully virtually administered ketamine therapy sessions.

Market Mapping

Research and development dominates the industry’s competitive landscape

A majority of the businesses in the psychedelic industry focus on research and development (R&D), studying the benefits of psychedelic substances and conducting preclinical and clinical research. Other segments—such as cultivation, clinics, and delivery platforms—have started to evolve only recently, driven by the advancements in R&D and positive developments in the regulatory landscape. So in addition to R&D focused leaders Compass Pathways and MindMed, the industry is now seeing growth in vertically integrated psychedelic players such as Field Trip, Numinus, New Wave, and others listed in the table below.

Incumbents
Growth
Early
Seed
Pre-Seed
Cultivation/ Synthesis
?
Patent Portfolio
?
Research and Development
?
Clinics
?
AI/ Digital Platforms
?
Pharmaceuticals
Pharmaceuticals
Pharmaceuticals
Pharmaceuticals
Pharmaceuticals
Numinus
Field Trip Health
Mycotopia Therapies
CB Therapeutics
Orthogonal Thinker
Silo Wellness
Psilera Bioscience
New Wave Holdings
Core One Labs
Mindset Pharma
Xphyto Therapeutics
Creso Pharma
Mind Cure Health
BetterLife Pharma
PsyBio Therapeutics
Filament Health
PharmaDrug
HAVN Life Sciences
Albert Labs
Mydecine Innovations Group
Psygen Labs
Octarine Bio
Pure Extracts Corp
MindMed
GH Research
Compass Pathways
Revive Therapeutics
Braxia Scientific
Cybin
Enveric Biosciences
CaaMTech
Wesana Health
Orthogonal Thinker
Bexson Biomedical
Silo Pharma
Psilera Bioscience
MYND Life Sciences
Tryp Therapeutics
Small Pharma
Core One Labs
Awakn Life Sciences
Mindset Pharma
Lobe Sciences
Creso Pharma
Mind Cure Health
Clearmind Medicine
BetterLife Pharma
PsyBio Therapeutics
Filament Health
Aion Therapeutic
Johnson & Johnson
MAPS
Abbvie
Usona Institute
ATAI Life Sciences
MindMed
GH Research
Compass Pathways
Revive Therapeutics
Field Trip Health
Braxia Scientific
Eleusis
Mycotopia Therapies
Beckley Psytech
Cybin
Seelos Therapeutics
Gilgamesh Pharmaceuticals
Enveric Biosciences
CaaMTech
Wesana Health
PharmaTher
Bexson Biomedical
Silo Pharma
Psilera Bioscience
New Wave Holdings
MYND Life Sciences
Tryp Therapeutics
Small Pharma
Bright Minds
DemeRx
M2Bio Sciences
Awakn Life Sciences
Mindset Pharma
Lobe Sciences
Creso Pharma
Mind Cure Health
Entheon Biomedical
Clearmind Medicine
BetterLife Pharma
Filament Health
PharmaDrug
Albert Labs
Mydecine Innovations Group
Perception Neuroscience
Pilz Bioscience Corp
Lophora
Aion Therapeutic
Numinus
Field Trip Health
Braxia Scientific
Eleusis
Mycotopia Therapies
Wesana Health
Silo Wellness
Levitee Labs
New Wave Holdings
Core One Labs
Awakn Life Sciences
Ketamine One
Creso Pharma
Novamind
Mindbloom
ATAI Life Sciences
Field Trip Health
Tripp
PharmaTher
Mindleap
Ketamine One
Mind Cure Health
Mydecine Innovations Group

The Disruptors

Compass Pathways and MindMed are the most advanced R&D companies

Having advanced their lead drugs to Phase 2b clinical trials, Compass Pathways and MindMed can be safely considered the for-profit pioneers in psychedelic research. And in some cases, it could be said that psychedelic medicine companies might prioritize financial stability over groundbreaking research with a majority of the companies covered in this industry hub having pursued relatively early-stage listings, following a strategy employed by cannabis companies.

Looking at the industry as a whole, capital is concentrated with the four Nasdaq-listed companies: Compass and MindMed as well as their relatively younger peers ATAI Life sciences and GH Research. Other disruptors like Field Trip, Core One Labs, Silo Pharma, and Bright Minds are also eyeing Nasdaq-listings or uplistings with the hope of accelerating growth via enhanced investor visibility.

Among the privately held companies, Beckley Psytech and Gilgamesh Pharmaceuticals—which develop psychedelic-inspired medicines for neuropsychiatric conditions, have raised the most cash within the range of USD 30-40 million in venture funding.

Cultivation/ Synthesis

?

Disruptors

?
Funding in USD Millions
Field Trip Health
Public - Market cap USD 253.7 mn
Numinus
Public - Market cap USD 124.3 mn
Xphyto Therapeutics
Public - Market cap USD 75.0 mn
Mydecine Innovations Group
Public - Market cap USD 51.5 mn
Mindset Pharma
Public - Market cap USD 43.6 mn
Mycotopia Therapies
Public - Market cap USD 41.9 mn
Filament Health
Public - Market cap USD 25.0 mn
Core One Labs
Public - Market cap USD 22.4 mn
HAVN Life Sciences
Public - Market cap USD 22.1 mn
Mind Cure Health
Public - Market cap USD 21.2 mn
PsyBio Therapeutics
Public - Market cap USD 17.7 mn
BetterLife Pharma
Public - Market cap USD 15.2 mn
PharmaDrug
Public - Market cap USD 13.4 mn
Pure Extracts Corp
Public - Market cap USD 9.3 mn
Silo Wellness
Public - Market cap USD 2.0 mn
New Wave Holdings
Public - Market cap USD 1.8 mn
Creso Pharma
Public - Market cap Unknown
CB Therapeutics
8
Orthogonal Thinker
6
Psilera Bioscience
3
Watchlist
?
Psygen Labs
Octarine Bio
Albert Labs

Patent Portfolio

?

Disruptors

?
Funding in USD Millions
Compass Pathways
Public - Market cap USD 1.3 bn
GH Research
Public - Market cap USD 894.2 mn
MindMed
Public - Market cap USD 863.3 mn
Cybin
Public - Market cap USD 277.2 mn
Revive Therapeutics
Public - Market cap USD 123.3 mn
Awakn Life Sciences
Public - Market cap USD 45.6 mn
Mindset Pharma
Public - Market cap USD 43.6 mn
Filament Health
Public - Market cap USD 25.0 mn
Braxia Scientific
Public - Market cap USD 24.4 mn
Core One Labs
Public - Market cap USD 22.4 mn
Mind Cure Health
Public - Market cap USD 21.2 mn
Enveric Biosciences
Public - Market cap USD 20.6 mn
Wesana Health
Public - Market cap USD 19.3 mn
PsyBio Therapeutics
Public - Market cap USD 17.7 mn
Silo Pharma
Public - Market cap USD 15.6 mn
BetterLife Pharma
Public - Market cap USD 15.2 mn
Lobe Sciences
Public - Market cap USD 9.9 mn
Tryp Therapeutics
Public - Market cap USD 9.7 mn
MYND Life Sciences
Public - Market cap USD 7.2 mn
Aion Therapeutic
Public - Market cap USD 2.8 mn
Creso Pharma
Public - Market cap Unknown
Clearmind Medicine
Public - Market cap Unknown
Orthogonal Thinker
6
Psilera Bioscience
3
Small Pharma
1
Watchlist
?
CaaMTech
Bexson Biomedical

Research and Development

?

Disruptors

?
Funding in USD Millions
Compass Pathways
Public - Market cap USD 1.3 bn
GH Research
Public - Market cap USD 894.2 mn
MindMed
Public - Market cap USD 863.3 mn
ATAI Life Sciences
Public - Market cap USD 843.2 mn
Cybin
Public - Market cap USD 277.2 mn
Field Trip Health
Public - Market cap USD 253.7 mn
Seelos Therapeutics
Public - Market cap USD 148.7 mn
Revive Therapeutics
Public - Market cap USD 123.3 mn
Mydecine Innovations Group
Public - Market cap USD 51.5 mn
Awakn Life Sciences
Public - Market cap USD 45.6 mn
Mindset Pharma
Public - Market cap USD 43.6 mn
Mycotopia Therapies
Public - Market cap USD 41.9 mn
Bright Minds
Public - Market cap USD 30.8 mn
Filament Health
Public - Market cap USD 25.0 mn
Braxia Scientific
Public - Market cap USD 24.4 mn
Mind Cure Health
Public - Market cap USD 21.2 mn
Enveric Biosciences
Public - Market cap USD 20.6 mn
Wesana Health
Public - Market cap USD 19.3 mn
PharmaTher
Public - Market cap USD 18.7 mn
Silo Pharma
Public - Market cap USD 15.6 mn
BetterLife Pharma
Public - Market cap USD 15.2 mn
PharmaDrug
Public - Market cap USD 13.4 mn
M2Bio Sciences
Public - Market cap USD 13.3 mn
Entheon Biomedical
Public - Market cap USD 12.7 mn
Lobe Sciences
Public - Market cap USD 9.9 mn
Tryp Therapeutics
Public - Market cap USD 9.7 mn
MYND Life Sciences
Public - Market cap USD 7.2 mn
Aion Therapeutic
Public - Market cap USD 2.8 mn
New Wave Holdings
Public - Market cap USD 1.8 mn
Creso Pharma
Public - Market cap Unknown
Clearmind Medicine
Public - Market cap Unknown
Beckley Psytech
114
Gilgamesh Pharmaceuticals
30
Eleusis
6
Psilera Bioscience
3
Small Pharma
1
DemeRx
1
Watchlist
?
CaaMTech
Bexson Biomedical
Albert Labs
Perception Neuroscience
Pilz Bioscience Corp
Lophora

Clinics

?

Disruptors

?
Funding in USD Millions
Field Trip Health
Public - Market cap USD 253.7 mn
Numinus
Public - Market cap USD 124.3 mn
Awakn Life Sciences
Public - Market cap USD 45.6 mn
Mycotopia Therapies
Public - Market cap USD 41.9 mn
Levitee Labs
Public - Market cap USD 29.5 mn
Braxia Scientific
Public - Market cap USD 24.4 mn
Ketamine One
Public - Market cap USD 24.4 mn
Novamind
Public - Market cap USD 22.4 mn
Core One Labs
Public - Market cap USD 22.4 mn
Wesana Health
Public - Market cap USD 19.3 mn
Silo Wellness
Public - Market cap USD 2.0 mn
New Wave Holdings
Public - Market cap USD 1.8 mn
Creso Pharma
Public - Market cap Unknown
Eleusis
6
Watchlist
?
Mindbloom

AI/ Digital Platforms

?

Disruptors

?
Funding in USD Millions
ATAI Life Sciences
Public - Market cap USD 843.2 mn
Field Trip Health
Public - Market cap USD 253.7 mn
Mydecine Innovations Group
Public - Market cap USD 51.5 mn
Ketamine One
Public - Market cap USD 24.4 mn
Mind Cure Health
Public - Market cap USD 21.2 mn
PharmaTher
Public - Market cap USD 18.7 mn
Tripp
15
Mindleap
1

Field Trip Health

Toronto-based Field Trip is a mental wellness company developing and delivering psychedelic therapies to treat mental disorders such as depression, post-traumatic stress disorder (PTSD), and anxiety. The company has three divisions: Health (clinics), Discovery (research and development), and Digital (virtual therapy). 

As of November 2021, Field Trip Health operates nine clinics across North America: New York, Los Angeles, Toronto, Atlanta, Chicago, Houston, Seattle, Fredericton, and Vancouver. The company also has near-term plans to open nine new clinics in locations including San Diego, San Carlos, Washington DC and Amsterdam. These clinics support ketamine-assisted therapies with plans to add other substances, including psilocybin, when permitted. Through its Discovery segment in research labs at the University of West Indies in Jamaica, the company is developing FT-104, its first drug candidate similar to psilocybin in potency. The research is at the preclinical evaluation stage and Field Trip is planning to launch its Phase I clinical trials in the first half of 2022. It also introduced a new pipeline research program (FT-200) to discover novel psychedelics for cardiovascular risks. 

In August 2020, Field Trip launched its free digital app which provides a framework and tools to support meditation and breathwork. The company also has a digital portal that provides users with information and tools related to psychedelic therapies to enhance and optimize the therapeutic experience provided via its clinics. 

Field Trip’s key strategy is to use the clinic model for immediate revenue generation while also making them an integral part of the company’s R&D structure. It plans to expand its clinic network to 20 by the end of 2021 and 75 by 2023. 

The company went public on the Canadian Securities Exchange in October 2020 after a reverse takeover of Newton Energy Corporation. The company was also listed on Nasdaq under the ticker symbol “FTRP” in July 2021. It recorded revenue of nearly CAD 1 million (USD 0.8 million) for the year ended March 2021 and earned a net loss of CAD 23 million (USD 19 million).

Segment:
Cultivation/ Synthesis
Total funding:
USD 19.5 million
Competitors:
Compass Pathways, Braxia Scientific, Numinus
Disruptor Funding History

Cultivation/ Synthesis :

Field Trip Health
Numinus
Core One Labs
Silo Wellness
New Wave Holdings
CB Therapeutics
Orthogonal Thinker
Psilera Bioscience
Psygen Labs
Octarine Bio

Patent Portfolio:

Compass Pathways
GH Research
MindMed
Cybin
Revive Therapeutics
Braxia Scientific
Core One Labs
Enveric Biosciences
Wesana Health
Silo Pharma
Tryp Therapeutics
MYND Life Sciences
Orthogonal Thinker
Psilera Bioscience
Small Pharma
CaaMTech
Bexson Biomedical

Research and Development:

The Incumbents

Industry yet to attract interest from big pharma

The psychedelic industry has not yet attracted major interest from conventional pharmaceutical companies. This reluctance could be due to psychedelic therapies’ tendency to require a single round of treatment as well as financial, legal, and reputational risks. Partnerships and acquisitions are highly likely in the near future, however, as psychedelic companies progress toward latter stages of drug development.

In-house development

Acquisition

Partnership

Investment

company-logo-0Johnson & Johnson
check
company-logo-1MAPS
check
company-logo-2Abbvie
check
company-logo-3Usona Institute
check
Johnson & Johnson

In May 2019, Johnson and Johnson, through its pharmaceutical unit Janssen Pharmaceutica, was the first in the industry to receive US Food and Drug Administration (FDA) approval for a psychedelic-like nasal spray, named Spravato, to treat depression. Spravato contains esketamine, a chemical derivative of ketamine, and is intended to be used in conjunction with oral antidepressants. Spravato prescriptions are limited to  patients who have tried and failed at least two different antidepressants. 

The FDA granted Breakthrough Therapy status to Spravato twice: for treatment-resistant depression in 2013 and for major depressive disorder with imminent risk for suicide in 2016. The company claims Spravato to be the only approved medicine able to reduce depressive symptoms within 24 hours. The treatment’s clinical trials showed a 16-point decrease on the Montgomery-Asberg Depression Rating Scale after the first dose of the drug, compared to approximately 12 points in the standard care group. 

As the first Breakthrough Therapy approved for depression in three decades, industry analysts predicted Spravato to be a blockbuster drug for Johnson and Johnson. However, the treatment received criticism for not being cost effective from industry watchdogs, the Institute for Clinical and Economic Review (ICER) in the US, and the National Institute for Health and Care Excellence (NICE) in the UK. ICER concluded that Spravato would cost USD 198,000 per quality-adjusted life year, above the usual USD 150,000 threshold used to evaluate cost-effectiveness. NICE also claimed the true efficacy of the drug was difficult to determine due to issues in clinical trial design, and rejected the use of the nasal spray for National Health Service (NHS) for treatment of major depressive disorder.

Notable Investors

No investor data is available

Funding data are powered by Crunchbase
arrow
menuarrow
Unlock company details, featured industry reports, and news updates.
Book a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.